Work

From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies

Year: 2024

Type: editorial

Abstract: This editorial reviews advances in hepatocellular carcinoma (HCC) treatment, focusing on a triple therapy approach and biomarker discovery. Zhang et al discuss the synergistic potential of transarterial chemoembolization combined with tyrosine kinase inhibitors and PD-1 inhibitors. Meanwhile, Li et al identify protein tyrosine phosphatase non-receptor II (PTPN2) as a biomarker for poor prognosis and immune evasion in HCC. The studies highlight the importance of combined therapies and biomarkers in improving HCC treatment efficacy and patient outcomes, with PTPN2 emerging as a potential therapeutic target. This article supplements the aforementioned studies with more recent research advancements, focusing on the molecular mechanisms and clinical applications of biomarkers.

Source: World Journal of Gastrointestinal Oncology

DOI: 10.4251/wjgo.v16.i11.4518

Authors: Mo-Wei Kong, Yang Yu, Ying Wan, Yu Gao, Chun-Xiang Zhang

Institutions: Southwest Medical University, Chengde Medical University, Affiliated Hospital of Chengde Medical College, Rush University Medical Center

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4403713630

Cites: 18

Cited by: 2

Related to: 10